blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1656131

EP1656131 - USE OF BETAINE FOR TREATING INTERMITTENT CLAUDICATION [Right-click to bookmark this link]
Former [2006/20]USE OF BETAINE FOR TREATING ARTERITIS
[2010/28]
StatusNo opposition filed within time limit
Status updated on  06.01.2012
Database last updated on 24.04.2024
Most recent event   Tooltip20.05.2016Lapse of the patent in a contracting statepublished on 22.06.2016  [2016/25]
Applicant(s)For all designated states
Messadek, Jallal
Place des Béguinages, 2
4000 Liège / BE
[2006/20]
Inventor(s)01 / see applicant
...
 [2006/20]
Application number, filing date04737684.308.07.2004
[2006/20]
WO2004BE00101
Priority number, dateBE2003000040815.07.2003         Original published format: BE 200300408
[2006/20]
Filing languageFR
Procedural languageFR
PublicationType: A2 Application without search report
No.:WO2005004854
Date:20.01.2005
Language:FR
[2005/03]
Type: A2 Application without search report 
No.:EP1656131
Date:17.05.2006
Language:FR
The application published by WIPO in one of the EPO official languages on 20.01.2005 takes the place of the publication of the European patent application.
[2006/20]
Type: B1 Patent specification 
No.:EP1656131
Date:02.03.2011
Language:FR
[2011/09]
Search report(s)International search report - published on:EP16.06.2005
ClassificationIPC:A61K31/205, A61K31/616, A61P9/00, A61P9/14, A61P9/10, A61P7/10, A61P37/02, A61P15/10
[2006/20]
CPC:
A61K31/205 (EP,US); A61K31/616 (EP,US); A61P15/10 (EP);
A61P27/02 (EP); A61P37/02 (EP); A61P43/00 (EP);
A61P7/02 (EP); A61P7/10 (EP); A61P9/00 (EP);
A61P9/10 (EP); A61P9/14 (EP) (-)
C-Set:
A61K31/205, A61K2300/00 (EP,US);
A61K31/616, A61K2300/00 (US,EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/20]
Extension statesALNot yet paid
HRNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:VERWENDUNG VON BETAIN ZUR BEHANDLUNG VON CLAUDICATIO INTERMITTENS[2010/28]
English:USE OF BETAINE FOR TREATING INTERMITTENT CLAUDICATION[2010/28]
French:UTILISATION DE LA BETAINE POUR LE TRAITEMENT DE LA CLAUDICATION INTERMITTENTE[2010/28]
Former [2006/20]VERWENDUNG VON BETAIN ZUR
Former [2006/20]USE OF BETAINE FOR TREATING ARTERITIS
Former [2006/20]UTILISATION DE LA BETAINE POUR LE TRAITEMENT DES ARTERITES
Entry into regional phase14.02.2006National basic fee paid 
14.02.2006Designation fee(s) paid 
14.02.2006Examination fee paid 
Examination procedure10.02.2006Amendment by applicant (claims and/or description)
14.02.2006Examination requested  [2006/20]
19.06.2007Despatch of a communication from the examining division (Time limit: M06)
19.12.2007Reply to a communication from the examining division
15.12.2008Despatch of a communication from the examining division (Time limit: M06)
25.06.2009Reply to a communication from the examining division
28.05.2010Cancellation of oral proceeding that was planned for 15.06.2010
15.06.2010Date of oral proceedings (cancelled)
18.06.2010Communication of intention to grant the patent
14.10.2010Fee for grant paid
14.10.2010Fee for publishing/printing paid
Opposition(s)05.12.2011No opposition filed within time limit [2012/06]
Fees paidRenewal fee
14.02.2006Renewal fee patent year 03
05.12.2007Renewal fee patent year 04
11.12.2008Renewal fee patent year 05
25.11.2009Renewal fee patent year 06
22.12.2010Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.07.200704   M06   Fee paid on   05.12.2007
31.07.200805   M06   Fee paid on   11.12.2008
31.07.200906   M06   Fee paid on   25.11.2009
31.07.201007   M06   Fee paid on   22.12.2010
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
TR02.03.2011
BG02.06.2011
AT08.07.2011
PL08.07.2011
HU09.07.2011
MC31.07.2011
[2016/25]
Former [2013/44]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
TR02.03.2011
BG02.06.2011
AT08.07.2011
PL08.07.2011
HU09.07.2011
MC31.07.2011
Former [2013/21]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
RO02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
AT08.07.2011
PL08.07.2011
HU09.07.2011
MC31.07.2011
Former [2013/10]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
RO02.03.2011
SE02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
AT08.07.2011
PL08.07.2011
HU09.07.2011
MC31.07.2011
Former [2013/07]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
SE02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
AT08.07.2011
PL08.07.2011
HU09.07.2011
MC31.07.2011
Former [2012/49]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
SE02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
PL08.07.2011
HU09.07.2011
MC31.07.2011
Former [2012/21]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
SE02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
HU09.07.2011
MC31.07.2011
Former [2012/11]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
SE02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
MC31.07.2011
Former [2011/51]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
SE02.03.2011
SI02.03.2011
SK02.03.2011
BG02.06.2011
Former [2011/48]CY02.03.2011
EE02.03.2011
FI02.03.2011
IE02.03.2011
SE02.03.2011
SI02.03.2011
BG02.06.2011
Former [2011/37]CY02.03.2011
FI02.03.2011
SE02.03.2011
SI02.03.2011
BG02.06.2011
Cited inInternational search[X]FR2119889  (VEGETTI TIBERIO) [X] 1,2,7-18,24,29,32 * page 1, line 1 - line 23 * * page 2, line 22 - line 24 * * page 3, line 19 - line 23 * * claims 1,2 *;
 [A]WO9515750  (HASHIM SAMI A [US]) [A] 1-5,7-21,23,24,29,32,33 * page 1, paragraph 2 * * page 5, paragraph 2 * * page 69, paragraph 2 - paragraph 4 * * page 10, paragraph 2 - page 11, paragraph 3 * * example 1 * * claims 1,2,8,10,12,13 *;
 [X]US5716941  (RABINOFF MICHAEL [US]) [X] 1-4,7-20,29,32,33 * column 1, line 9 - line 12 * * column 2, line 42 - line 50 * * column 3, line 44 - line 52 * * column 4, line 24 - line 34 * * column 5, line 1 - line 12 *;
 [XA]WO9819690  (BRISTOL MYERS SQUIBB CO [US]) [X] 1,2,7-18,29,32 * page 1, line 4 - line 10 * * page 3, line 19 - line 33 * * page 5, line 7 - line 20 * * page 6, line 16 - line 19 * * page 10, line 20 - page 11, line 9 * * claims 16-19 * [A] 3,4,19,20,33;
 [DX]WO0025764  (MERCK PATENT GMBH [DE], et al) [DX] 1-3,7-19,29,32 * page 2, line 16 - page 3, line 2 * * page 5, line 16 - page 6, line 8 * * page 7, line 1 - line 3 * * page 9, line 1 - line 5 * * page 10, line 25 - page 11, line 20 * * example 1 * * claims 1,2,7-11 *;
 [DA]WO02062322  (MESSADEK JALLAL [BE]) [DA] 1-3,5,7-19,21,23,24,29,32 * page 1, line 5 - line 9 * * page 7, line 11 - line 26 * * page 20, line 11 - line 21 * * page 27, line 24 - page 28, line 4 * * examples 29,30,33 *;
 [X]US2002183380  (HUNTER WILLIAM L [CA]) [X] 1-3,5,7-17,21,23,24,29,32 * page 1, paragraph 2 * * page 3, paragraph 29 * * page 12, paragraphs 139,140 * * page 11, paragraph 130 * * pages 23-24, paragraphs 213-215 * * pages 24-25, paragraph 223 * * pages 25-26, paragraphs 227,228 * * pages 29-30, paragraphs 255-257 *;
 [DPX]WO2004049095  (MESSADEK JALLAL [BE], et al) [DPX] 1-22,29,32,33 * page 1, line 5 - line 24 * * page 7, line 16 - page 8, line 3 * * page 10, line 15 - line 20 * * page 17, line 24 - page 18, line 8 * * page 25, line 4 - line 27 * * page 30, line 26 - page 31, line 7 * * examples 1,3 * * page 62, line 10 - line 14 * * page 64, line 15 - line 20 * * page 65, line 1 - line 5 * * page 68, line 4 - line 6 ** claims 1,9,14,15,40 *;
 [Y]  - "BETAINE FOR HOMOCYSTINURIA", MEDICAL LETTER ON DRUGS AND THERAPEUTICS, NEW ROCHELLE, NY, US, (19970131), vol. 39, no. 993, ISSN 0025-732X, page 12, XP000853853 [Y] 1-4,7-20,23,24,32,33 * the whole document *
 [Y]  - MALINOW M R (REPRINT), "PLASMA HOMOCYST(E)INE AND ARTERIAL OCCLUSIVE DISEASES - A MINIREVIEW", CLINICAL CHEMISTRY, (JAN 1995) VOL. 41, NO. 1, PP. 173-176. ISSN: 0009-9147., (199501), XP008039186 [Y] 1-3,32 * page 173, column 1, paragraphs 1,2 * * page 175, column 1, paragraph 2 - paragraph 3 * * page 175, column 2, paragraph 3 *
 [Y]  - AL-AWAMI M ET AL, "Homocysteine levels in patients with Raynaud's phenomenon", VASA - JOURNAL OF VASCULAR DISEASES 2002 SWITZERLAND, (2002), vol. 31, no. 2, ISSN 0301-1526, pages 87 - 90, XP008039171 [Y] 23 * abstract * * page 88, column 1, paragraph 2 * * page 89, column 1, paragraph 7 - column 2, paragraph 1 *
 [Y]  - DIDIER A -F ET AL, "Distal cutaneous necrosis, an unusual etiology: Hyperhomocysteinemia", ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, (199911), vol. 126, no. 11, ISSN 0151-9638, pages 822 - 825, XP008039169 [Y] 1-4,7-20,32,33 * abstract * * page 823, column 2, paragraph 3 - page 824, column 1, paragraph 1 *
 [Y]  - STAMMLER F ET AL, "Prevalence of hyperhomocysteinaemia in thrombangiitis obliterans (Buerger's disease): Does homocysteine play a pathogenetic role?", DMW (DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT), (1996), vol. 121, no. 46, ISSN 0012-0472, pages 1417 - 1423, XP008039176 [Y] 24 * abstract * * page 1421, column 1, paragraph 1 *
Examination   - HIATT WILLIAM R., "Medical treatment of peripheral arterial disease and claudication", NEW ENGLAND JOURNAL OF MEDICINE, (20010524), vol. 344, no. 21, doi:doi:10.1056/NEJM200105243442108, ISSN 0028-4793, pages 1608 - 1621, XP009006719

DOI:   http://dx.doi.org/10.1056/NEJM200105243442108
    - MANGIAFICO R.A., "Pharmacotherary for intermittent claudication: from consensus-based to evidence-based treatment", VASCULAR DISEASE PREVENTION, (2004), vol. 1, doi:doi:10.2174/1567270043480869, pages 1 - 15, XP008046989

DOI:   http://dx.doi.org/10.2174/1567270043480869
    - NORVIT TRIAL INVESTIGATORS, "Homocysteine lowering and cardiovascular events after acute myocardial infarction", NEW ENGLAND JOURNAL OF MEDICINE, (200604), vol. 354, no. 15, doi:doi:10.1056/NEJMoa055227, ISSN 0028-4793, pages 1578 - 1588, XP008094823

DOI:   http://dx.doi.org/10.1056/NEJMoa055227
    - LONN EVA ET AL, "Homocysteine lowering with folic acid and B vitamins in vascular disease", NEW ENGLAND JOURNAL OF MEDICINE, (200604), vol. 354, no. 15, doi:doi:10.1056/NEJMoa060900, ISSN 0028-4793, pages 1567 - 1577, XP008098038

DOI:   http://dx.doi.org/10.1056/NEJMoa060900
    - DUPREZ D. ET AL, "Estimation of walking distance in intermittent claudication: Need for standardization", EUROPEAN HEART JOURNAL, (199905), vol. 20, no. 9, ISSN 0195-668X, pages 641 - 644
    - INTERNET CITATION, URL: http://www.umm.edu/patiented/articles/intermittent_claudication_other_symptoms_of_peri...
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.